Imugene’s CF33-hNIS (VAXINIA) & MAST study featured at ASCO GI Cancers Symposium

On January 19, 2024 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported further details from its poster presentation at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco (Press release, Imugene, JAN 19, 2024, https://mcusercontent.com/e38c43331936a9627acb6427c/files/39befa96-9c07-f014-8948-4f0774a3ed3b/Imugene_CF33_hNIS_VAXINIA_MAST_Study_Featured_at_ASCO_GI.pdf [SID1234639339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster "Oncolytic Virus CF33-hNIS Monotherapy for the Treatment of Gastrointestinal Malignancies" was presented at 11:45am-1:15pm Pacific time on 18 January 2024 during Session A: Cancers of the Esophagus and Stomach and Other GI Cancers.

Dr Daneng Li, from the City of Hope National Comprehensive Cancer Centre presented the poster which detailed background on CF33, the MAST study design, objectives and results observed to date.

Conclusions of the poster presentation included:

Preliminary data from the first three dose levels demonstrates encouraging anti-tumor activity with CF33-hNIS monotherapy, including one patient with cholangiocarcinoma, treated intratumorally, who achieved an immunological complete response (CR) with no known recurrence after one year.
CF33-hNIS monotherapy may be an effective and safe treatment option for GI (gastrointestinal) malignancies and warrants further investigation in biliary tract cancer patients.
Immunological changes in CF33-hNIS responding patients show a robust innate and adaptive immune response known to promote anti-tumor immunity and underscores the immunomodulatory potential of this therapy.
The poster can be downloaded from the Imugene website at: View Source

ASCO-GI is an annual international event highlighting the latest innovative science, strategies, developments and breakthroughs in gastrointestinal cancer treatment. It is estimated that more than 4,000 scientific figures, clinical researchers, academics, oncologists and medical practitioners from around the world attend the event.